The partnership builds on Cancer Research U.K.'s existing Grand Challenge initiative, which funds seven international teams across nine countries. Cancer Grand Challenges will use a highly competitive process designed to stimulate scientific creativity and bold advances in cancer research to improve outcomes for people affected by cancer.

The goals of the partnership between the two agencies include:

• Identifying important cancer research opportunities
• Facilitating global collaboration among multidisciplinary researchers to solve these challenges
• Giving the global teams the freedom and scale to innovate and carry out cutting-edge research
• Further advancing fundamental biological knowledge and its clinical application to cancer

NCI and Cancer Research U.K. will announce the list of new challenges in October 2020. Challenges will be determined through a series of international workshops to receive input from thought leaders from the cancer research community and a patient committee.

Submissions from research teams will be accepted from October 2020 through April 2021. From the submissions, a small number will be selected to receive pilot funds to further develop their ideas into larger, final applications. This funding will be announced in June 2021 and the awards to the final teams will be announced in 2022.

The agencies are expected to co-fund approximately four awards for each round of Cancer Grand Challenges, with each team receiving $25 million over five years. Three rounds of challenges are expected, with a new round announced every other year.

ESMO recommends use of NGS for advanced cancers
The European Society for Medical Oncology (ESMO) released its first recommendations for the use of next-generation sequencing (NGS) for patients with...

Cancer research groups partner for liquid biopsy trial
The Cancer Research Institute and the Mark Foundation for Cancer Research have partnered on a clinical trial to evaluate whether a novel liquid biopsy...

Cancer Research UK, Abcam partner on cancer antibodies
Abcam will create protein-based reagents for targets identified by Cancer UK-funded researchers. Antibodies that result from the partnership will be used...